Tier 2 — strong

Efficacy and tolerability of EH301 for amyotrophic lateral sclerosis: a randomized, double-blind, placebo-controlled human pilot study

de la Rubia JE, Drehmer E, Platero JL, Benlloch M, Caplliure-Llopis J, Villaron-Casales C, de Bernardo N, AlarcÓn J, Fuente C, Carrera S, Sancho D, GarcÍa-Pardo P, Pascual R, JuÁrez M, Cuerda-Ballester M, Forner A, Sancho-Castillo S, Barrios C, Obrador E, Marchio P, Salvador R, Holmes HE, Dellinger RW, Guarente L, Estrela JM
Amyotrophic lateral sclerosis & frontotemporal degeneration 2019 20; 1-2; 115-122

Bibliography

PubMed
PMID 30668199
DOI
10.1080/21678421.2018.1536152
Funding
Funding details are not specified in the accessible publication information.
Competing interests
A complete competing-interest declaration is not specified in the accessible publication information.

Study snapshot

DesignRandomized controlled study of a multi-ingredient or combined intervention
ModelHuman participants
Sample32 people with ALS recruited; 20 completed
InterventionEH301: NR plus pterostilbene versus placebo
Duration4 months
EndpointsALS functional rating; respiratory function; strength

What the study showed, in plain terms

This small EH301 pilot reported favorable functional, respiratory and strength measures compared with placebo.

Key findings

This small EH301 pilot reported favorable functional, respiratory and strength measures compared with placebo.

What this study can and cannot tell us

Substantial attrition, baseline imbalance concerns and combination treatment. The study does not establish NR monotherapy or confirmed disease modification.

Related papers in the corpus

Tier 4
Nicotinamide riboside and pterostilbene reduces frequency and severity of undesirable symptoms of the menopause transition: an open-label, pilot clinical trial
Holmes HE et al. · Frontiers in aging · 2026
Tier 2
Nicotinamide riboside and pterostilbene reduces markers of hepatic inflammation in NAFLD: A double-blind, placebo-controlled clinical trial
Dellinger RW et al. · Hepatology (Baltimore, Md.) · 2023
Tier 2
Effect of the Mediterranean diet supplemented with nicotinamide riboside and pterostilbene and/or coconut oil on anthropometric variables in amyotrophic lateral sclerosis. A pilot study
Carrera-Juliá S et al. · Frontiers in nutrition · 2023
Tier 2
A randomized placebo-controlled trial of nicotinamide riboside and pterostilbene supplementation in experimental muscle injury in elderly individuals
Jensen JB et al. · JCI insight · 2022
Tier 2
Nicotinamide riboside with pterostilbene (NRPT) increases NAD + in patients with acute kidney injury (AKI): a randomized, double-blind, placebo-controlled, stepwise safety study of escalating doses of NRPT in patients with AKI
Simic P et al. · BMC nephrology · 2020
Tier 2
Repeat dose NRPT (nicotinamide riboside and pterostilbene) increases NAD + levels in humans safely and sustainably: a randomized, double-blind, placebo-controlled study
Dellinger RW et al. · NPJ aging and mechanisms of disease · 2017

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology